Skip to main content

LENZ Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 11, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 11, 2026

LENZ$4.10-4.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except share data)

Stockholders' Equity
Common Stock · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · Stockholders' Equity
Shares · Amount
Balance as of December 31, 202531,344,782$1$511,237$(227,141)$242$284,339
Exercise of stock options2,698—14——14
Unrealized loss on marketable securities————(692)(692)
Vesting of restricted stock units6,914—————
Share-based compensation——4,319——4,319
Net loss———(41,488)—(41,488)
Balance as of March 31, 202631,354,394$1$515,570$(268,629)$(450)$246,492
Stockholders' Equity
Common Stock · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · Stockholders' Equity
Shares · Amount
Balance as of December 31, 202427,518,439$1$348,901$(145,014)$196$204,084
Exercise of stock options11,630—44——44
Unrealized loss on marketable securities————(73)(73)
Vesting of early exercised stock options5,594—19——19
Share-based compensation——2,555——2,555
Net loss———(14,619)—(14,619)
Balance as of March 31, 202527,535,663$1$351,519$(159,633)$123$192,010
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.